Related Experiment Video
Updated: Jan 17, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Bridging EGFR/TGF-β Signaling to Bypass Resistance to Immune Checkpoint Blockade
Noura J Choudhury1, Aditi Kothari2, Christine M Bestvina1
1Department of Medicine, University of Chicago, Chicago, Illinois.
None:
Although EGFR is a common target in squamous cancers, anti-EGFR monotherapies have shown modest success because of existing or acquired activation of other oncogenic pathways and tumor heterogeneity. A bifunctional fusion protein ficerafusp alfa in combination with pembrolizumab represents a potential solution to overcome resistance in early-phase clinical investigation. See related article by Hernando-Calvo et al., p. 4623.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
09:04Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
Related Concept Videos
Mitogens and the Cell Cycle
Tumor Immunotherapy
TGF - β Signaling Pathway
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The Tumor Microenvironment